Order Article Reprints

Claveria-Cabello A, Colyn L, Uriarte I, Latasa MU, Arechederra M, Herranz JM, Alvarez L, Urman JM, Martinez-Chantar ML, Banales JM, et al. Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Cancers. 2020; 12(12):3748. https://doi.org/10.3390/cancers12123748

Claveria-Cabello, Alex, Leticia Colyn, Iker Uriarte, Maria Ujue Latasa, Maria Arechederra, Jose M. Herranz, Laura Alvarez, Jesus M. Urman, Maria L. Martinez-Chantar, Jesus M. Banales, and et al. 2020. "Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis" Cancers 12, no. 12: 3748. https://doi.org/10.3390/cancers12123748

Claveria-Cabello, A., Colyn, L., Uriarte, I., Latasa, M. U., Arechederra, M., Herranz, J. M., Alvarez, L., Urman, J. M., Martinez-Chantar, M. L., Banales, J. M., Sangro, B., Rombouts, K., Oyarzabal, J., Marin, J. J. G., Berasain, C., Avila, M. A., & Fernandez-Barrena, M. G. (2020). Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Cancers, 12(12), 3748. https://doi.org/10.3390/cancers12123748